Amedisys (AMED)
(Delayed Data from NSDQ)
$96.71 USD
-0.09 (-0.09%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $96.71 0.00 (0.00%) 6:06 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.71 USD
-0.09 (-0.09%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $96.71 0.00 (0.00%) 6:06 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Zacks News
Can Breast Health Growth Aid Hologic (HOLX) in Q3 Earnings?
by Zacks Equity Research
Hologic (HOLX) is expected to deliver strong third-quarter fiscal 2019 results on robust performance of the breast health segment.
Use Rising P/E Strategy to Buy 5 Winning Stocks
by Sanghamitra Saha
Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.
Can Home Health Growth Support Amedisys' (AMED) Q2 Earnings?
by Zacks Equity Research
Within Home Health, Amedisys (AMED) is expected to boost same-store volumes in Q2 via higher admissions and re-certifications.
Can Sequencing Products Drive Illumina's (ILMN) Q2 Earnings?
by Zacks Equity Research
Illumina (ILMN) is expected to deliver a strong second quarter on impressive performance by sequencing portfolio.
What's in the Offing for PerkinElmer's (PKI) Earnings in Q2?
by Zacks Equity Research
Top-line growth and robust performance at Diagnostics segment are likely to aid PerkinElmer's (PKI) Q2 earnings. However, forex is likely to be a dampener.
What's in Store for Boston Scientific's (BSX) Q2 Earnings?
by Zacks Equity Research
We are upbeat about solid contributions from Boston Scientific's (BSX) Cardiovascular business group, which comprises Interventional Cardiology and Peripheral Interventions.
Can NovoCure's (NVCR) Steady Optune Business Aid Q2 Earnings?
by Zacks Equity Research
NovoCure (NVCR) expects to deliver a strong second quarter on solid performance by Optune business.
Will Core MedSurg Segment Drive Stryker's (SYK) Q2 Earnings?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat second quarter 2019 view are likely to fuel Stryker's (SYK) Q2 earnings. However, forex might be a woe.
Baxter (BAX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter (BAX) expects second-quarter revenues to decline 2% on a reported basis.
Zacks.com featured highlights include: Ross Stores, Shoe Carnival, Stitch Fix, Amedisys and NVR
by Zacks Equity Research
Zacks.com featured highlights include: Ross Stores, Shoe Carnival, Stitch Fix, Amedisys and NVR
Can Amedisys (AMED) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
5 Top-Ranked Stocks Empowered by DuPont Analysis
by Sanghamitra Saha
Have more faith in DuPont analysis than simple ROE calculation and bet on these five stocks.
Amedisys Rides on New Buyouts, Strength in Personal Care Arm
by Zacks Equity Research
Amedisys' (AMED) recently-integrated Personal Care segment is attaining stability and living up to expectation.
Bet on These 5 Stocks With Exciting Interest Coverage Ratio
by Sumit Singh
Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.
Amedisys (AMED) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks.com featured highlights include: Medifast, Shoe Carnival, Marine Products, Amedisys and NVR
by Zacks Equity Research
Zacks.com featured highlights include: Medifast, Shoe Carnival, Marine Products, Amedisys and NVR
Top Ranked Momentum Stocks to Buy for June 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 21st.
Bet Big on DuPont Analysis With These Top 5 Picks
by Sanghamitra Saha
Do you have more faith in DuPont analysis than a simple ROE calculation? Bet on these five stocks then.
Here is Why Growth Investors Should Buy Amedisys (AMED) Now
by Zacks Equity Research
Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks.com featured highlights include: Intuit, Insperity, Amedisys, Pioneer Natural and Century Casinos
by Zacks Equity Research
Zacks.com featured highlights include: Intuit, Insperity, Amedisys, Pioneer Natural and Century Casinos
5 Stocks With Impressive Interest Coverage Ratio to Buy Now
by Sumit Singh
Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.
Zacks.com featured highlights include: Shoe Carnival, Ulta, Amedisys, NVR and EMCOR
by Zacks Equity Research
Zacks.com featured highlights include: Shoe Carnival, Ulta, Amedisys, NVR and EMCOR
3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Amedisys (AMED) Down 9.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Trade War Scaring You? Buy 5 DuPont-Tested Quality Stocks
by Sanghamitra Saha
Bet on five top-ranked stocks with higher ROE derived the DuPont way.